In the I-SPY 2 trial, investigators analyzed whether MammaPrint scores and BluePrint subtypes could help identify patients who would respond better to treatments.
The company said it plans to use the financing to increase adoption of its MammaPrint BluePrint next-generation sequencing-based test kit for breast cancer.
Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.
The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
The company hopes that meeting the needs of a more decentralized testing model will increase access to its products for European women with breast cancer.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
